(Q33832848)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

New insights into the pharmacodynamic and pharmacokinetic properties of statins (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Roberta Baetta

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

S Bellosta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

R Fumagalli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

R Paoletti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

F Bernini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 December 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

Pharmacology & Therapeutics

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

413-428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

Lovastatin. Warfarin interaction

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Cardiovascular complications after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Roche, FDA announce new drug-interaction warnings for mibefradil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Lovastatin and rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

PROAPOPTOTIC EFFECT OF ATORVASTATIN ON STIMULATED RABBIT SMOOTH MUSCLE CELLS

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Drug interactions of lipid-altering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Direct vascular effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal Macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Coronary artery disease in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pharmacology of competitive inhibitors of HMG-CoA reductase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Direct effects of statins on the vascular wall

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Binding of 2',3'-cyclic nucleotide 3'-phosphodiesterase to myelin: an in vitro study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Post-translational modification of human brain type I inositol-1,4,5-trisphosphate 5-phosphatase by farnesylation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Matrix metalloproteinases and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Physiological disposition of HMG-CoA-reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Coronary Plaque Disruption

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

HMG CoA reductase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Simvastatin during warfarin therapy in hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in an atherosclerotic hypercholesterolemic rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Prenyl proteins in eukaryotic cells: a new type of membrane anchor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Single-Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Management of primary hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effect of fluvastatin for safely loweringatherogenic lipids in renal transplant patients receiving cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Endocrine and metabolic abnormalities following kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

G beta gamma interactions with PH domains and Ras-MAPK signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Apoptosis in human atherosclerosis and restenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Updated clinical safety experience with fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: three-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Persistent hyperlipidemia in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Lipid-lowering therapy for patients with or at risk of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Potential warfarin-fluvastatin interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Cyclosporin A hepatotoxicity in 66 renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Foam cell replication and smooth muscle cell apoptosis in human saphenous vein grafts.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Cholesterol-lowering agent myopathy (CLAM)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Posttranslational modification of proteins by isoprenoids in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effects of Fluvastatin on Leukocyte–Endothelial Cell Adhesion in Hypercholesterolemic Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

1 reference

7 January 2021

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses*

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents. An analysis of a clinical trial database

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Clinical pharmacokinetics of pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Lovastatin, nicotinic acid, and rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Interaction between fibre and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Rhabdomyolysis due to interaction of simvastatin with mibefradil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pharmacokinetics of fluvastatin and specific drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Atorvastatin does not alter the anticoagulant activity of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

In vitro and in vivo drug interactions involving human CYP3A.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Potential interaction between warfarin and fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Binding of fluvastatin to blood cells and plasma proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Simvastatin: the clinical profile

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

The human drug metabolizing cytochromes P450.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Protein prenylation: molecular mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900045-5

7 January 2021

10.1016/S0163-7258(99)00045-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665838%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference